Stay invested in Ipca Laboratories: Phani Sekhar

Phani Sekhar of Angel Broking told CNBC-TV18, "Ipca Laboratories looks good. The future is even more promising, because it is looking at some good launches in the US and also new launches in branded markets. All in all among the midcap pharma companies this is one company that you can look forward to."

"A mild challenge that the street is expecting significant ramp up in its margins and it is valuing Ipca accordingly. While you can look at a 18 percent CAGR for next three years in terms of increasing sales both on the back of increasing export sales as well as ramp up in domestic business if for some reason the margin expansion does not come through then there might be some disappointment. However, on the balance I would like to advise the investor to hold onto Ipca and over a period of time one can look at a return of 15-20 percent over the next 15-18 months," he added.